Company: Lupin
Title: Chief Executive Officer            Â
Industry: Pharmaceuticals
Standout achievement in 2025: Transformed Lupin's U.S. business into the nation's third-largest generic medicine supplier, launching roughly a dozen new medications and securing reappointment as CEO of Lupin for an additional five years.
As head of the world's seventh-largest pharmaceutical company by volume and the U.S.'s third-largest generic medicine supplier, Gupta has built Lupin's U.S. business from the ground up, leading major expansions in complex generics including inhalation and injectables, specialty and biosimilars.
In 2025, Gupta led the company during one of the most consequential shifts in America's medicine supply chain. Working with the Trump administration and the State of Florida, she advanced Lupin's U.S. reshoring initiative, announcing a new inhalation manufacturing facility in Coral Springs, anticipated to produce 25% of U.S. albuterol demand.
